Dianthus Therapeutics | MGTA - Ebitda


Dianthus Therapeutics reported $-40.19M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
Avita Medical AUD -21.9M 12.04M Jun/2025
Celltrion KRW 374.56B 352.67B Sep/2025
Cspc Pharmaceutical CNY 2.19B 21.88M Dec/2024
Dianthus Therapeutics USD -40.19M 5.36M Sep/2025
Divis Laboratories Ltd INR 8.88B 1.59B Sep/2025
IQVIA Holdings USD 949M 39M Sep/2025
Kangmei Pharma CNY 17.3M 20.56M Jun/2025
Knight Therapeutics CAD 15.51M 3.39M Jun/2025
Laboratorios Farma EUR 34.94M 102.95M Jun/2025
Malin Corporation EUR -1.1M 200K Dec/2024
Medical Developments International AUD 1.78M 3.78M Dec/2024
Moderna USD -208M 552M Sep/2025
Neuren Pharmaceuticals AUD 176.7M 166.79M Dec/2024
Organigram Holdings CAD 6.15M 455K Sep/2025
Organon & Co USD 518M 4M Sep/2025
Pharma Mar EUR -1.98M 28.13M Sep/2025
Qiagen NV USD 193.17M 15.81M Sep/2025
Revvity USD 248.91M 48.52M Dec/2025
Sartorius EUR 277.4M 30.5M Dec/2025
Sino Biopharmaceutical CNY 2.59B 1.57B Dec/2024
Tectonic Therapeutic USD -13.48M 5.73M Dec/2024
Tilray USD 8.36M 1.82M Sep/2025
Viatris USD 1.15B 75.8M Sep/2025
Xeris Pharmaceuticals USD 17.42M 8.83M Sep/2025
Zhangzhou Pientzehuang Pharmaceutical CNY 531.61M 658.23M Jun/2025